The field of oncology is undergoing a seismic shift as cellular reprogramming moves from the realm of clinical trials to frontline standard-of-care. The Chimeric Antigen Receptor T (CAR-T) Cells Market a cornerstone of the broader cell and gene therapy landscape, is entering its most explosive growth phase yet. Valued at USD 5.36 billion in 2024, the market is projected to reach a sta... https://shashikant873.livejournal.com/3767.html